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Abstract 
Myocardial fibroblast activation coupled with extracellular matrix production is a 
pathological signature of myocardial fibrosis and is governed mainly by transforming 
growth factor TGFβ-Smad2/3 signaling. Targeting the ubiquitous TGFβ leads to cellular 
homeostasis deregulation with adverse consequences. We previously showed the anti-
fibrotic effects upon downregulation of 90-kDa heat shock protein (Hsp90), a 
chaperone that associates to the TGFβ signaling cascade. In the present study, we use 
a fluorescent-labeled Hsp90 protein inhibitor (CTPR390-488) with specific Hsp90 
binding properties to reduce myocardial pro-fibrotic events in vitro and in vivo. The 
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mechanism of action involves the disruption of TGFβRI-Hsp90 complex, resulting in a 
decrease in TGFβ signaling and reduction in extracellular matrix collagen. In vivo, 
decreased myocardial collagen deposition was observed upon CTPR390-488 
treatment in a pro-fibrotic mouse model. This is the first study demonstrating the ability 
of an engineered Hsp90 protein inhibitor to block collagen expression, reduce the 
motility of myocardial TGFβ-activated fibroblasts and ameliorate angiotensin-II induced 
cardiac myocardial fibrosis in vivo. 
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1 Introduction 
Myocardial fibrosis is a common phenomenon in the late stages of diverse cardiac 
diseases and it is a predictive factor of poor cardiac recovery. The mechanical cues are 
known to activate cardiac fibroblasts resulting in their differentiation into myofibroblasts, 
proliferation and excessive extracellular matrix production and long-term matrix 
stiffening. These events result in structural and functional alterations of the heart. 
Myocardial fibrosis lacks an effective treatment; approaches to reduce fibrosis exploit 
the understanding of the fibroblasts’ role in the fibrotic process. Fibroblasts are the 
main contributors in the production of myocardial collagen principally through the 
transforming growth factor β (TGFβ) signaling pathway. TGFβ is the main pro-fibrotic 
cytokine. TGFβ exerts its effect by binding to a complex of TGFβ receptor I and II 
resulting in phosphorylation and translocation of Smad2/3 to the nucleus and 
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increasing collagen production. Collagen protein deposition increases the extracellular 
matrix network [1-3]. The highly conserved ATP-dependent chaperone heat shock 
protein 90 (Hsp90) has been described as a component of the TGFβ signaling cascade 
[4-7]. The Hsp90 family consists mainly of four members: Hsp90aa1 or Hsp90α, 
Hsp90ab1 or Hsp90β, gp96 and TNF receptor associated protein 1 (TRAP1). The most 
important isoforms are the inducible Hsp90α, expressed upon stress stimuli, and the 
constitutively expressed isoform Hsp90β. Apart from its classical role in protein folding, 
Hsp90 binds other proteins, like transcription factors. In regards to the TGFβ signaling 
cascade, Hsp90 inhibition was described to attenuate renal fibrosis through 
degradation of TGFβ type II receptor [4]. Hsp90 inhibition was found to reduce collagen 
I synthesis on hepatic stellate cells (HSCs) in liver fibrosis [8]. Interesting data 
described by different groups including ours, showed that pharmacological and 
biological inhibition of Hsp90 effectively blocks the pro-fibrotic effects of TGFβ in 
different preclinical models of skin fibrosis in systemic sclerosis [6], in cardiac 
hypertrophy [9] or in cardiac fibrosis [10]. Hsp90 was presented as a novel modulator 
of TGFβ signaling in lung adenocarcinoma and bronchoalveolar carcinoma cells [5]. 
Various Hsp90 inhibitors such as geldanamycin, radicicol, 17-AAG, 17-DMAG, AUY-
922, AT-13387, STA-9090, CNF-2024 are used to block Hsp90 activity in cancer with 
numerous side effects due to the inhibition of the ATPase domain, a key functional 
element in its Hsp90’s protein folding activity [11].  
A new class of small protein therapeutic agents have been described, derived from 
natural binding domains including ankyrin repeats, tetratricopeptide repeats, and other 
protein scaffolds [12-14]. Of particular interest is a previously designed Hsp90 binding 
module based on a tetratricopeptide repeat scaffold (CTPR390) that aims to inhibit 
Hsp90 minimizing the effects on cellular homeostasis  [15] [16]. The engineered TPR 
scaffold is a protein generated by tandem repeats of a small structural motif (34 amino 
acids) with a simple architecture, stabilized by local interactions between the repeated 
modules [16]; its secondary and tertiary structures are characterized by the 
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predominance of repeated and predictable local interactions. Therefore, there is a clear 
structural and functional delimitation between key residues encoding the stability and 
the functionality of the protein module [17]. These consensus TPRs (CTPRs) are 
scaffold proteins that can act as small antibody mimetics into which different ligand 
recognition properties can be encoded [18], thus opening the door to multiple  
biotechnological and biomedical applications. CTPR390 specifically binds the MEEVD 
sequence at the C-terminal region of the Hsp90 protein, which represents the 
recognition sequence for Hsp90 co-chaperones [19].  A fluorophore (Alexa 488) was 
incorporated to the final biomolecule (CTPR390-488) for both in vitro and in vivo 
tracking.  
One of the most studied in vivo small animal models developing myocardial fibrosis is 
the angiotensin II treated-mouse. The renin/angiotensin/aldosterone system plays an 
important role in normal myocardial function. However, chronic elevation in angiotensin 
II (Ang II) levels is associated with fibrosis among other pathological remodeling 
adverse effects [20]. TGFβ activation occurs downstream Ang II activity and implicates 
TGFβ–dependent collagen synthesis [21]. Ang II deregulation results in pathological 
remodeling, especially myocardial fibrosis [22], and its administration in animal models 
commonly induces left ventricular remodeling, progressive deterioration of cardiac 
function, and finally clinical syndrome of heart failure [23]. This mouse model of 
myocardial fibrosis was used to determine the effects of selective Hsp90 inhibition by 
the engineered protein CTPR390-488 on myocardial collagen synthesis and 
accumulation. We have previously pointed out the role for Hsp90 in sustaining TGFβ 
signaling and collagen synthesis in cardiac fibroblasts and also Datta et al. suggested 
that Hsp90 participates in cardiac remodeling in an in vivo model of cardiac fibrosis [7, 
9, 10]. The novelty of this paper resides in the use of an engineered protein that does 
not act by inhibiting the ATPase activity of Hsp90 but by mimicking co-chaperone 
binding to Hsp90. This binding results in the inhibition of collagen synthesis preserving 
cellular homeostasis.  
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2 Results  
2.1 CTPR390-488 is internalized in primary myocardial 
fibroblasts and does not affect cellular viability 
In vivo confocal imaging experiments revealed the presence of CTPR390-488 inside 
and outside primary cardiac fibroblasts treated with two different concentrations (0.2 
and 0.8 μM) of CTPR390-488 (Fig 1A). Cell viability at increasing concentrations of 
CTPR390-488 was not affected (Fig 1B). To assess the uptake efficiency of CTPR390-
488 into primary cells, colorimetric and fluorometric assays were performed at 24 hours 
after CTPR390-488 addition. The average percentage of CTPR390-488 internalization 
at all concentrations tested (0.0, 0.1, 0.2, 0.4, 0.8, 1.5, and 3 μM) was 9.1±3.3 % 
measured by absorbance (Fig 1C) or 9.3±4.6 %, when detected by fluorescence (Fig 
1D). The percentage of cellular uptake of the CTPR390-488 protein at each 
concentration was determined (Table 1 source data). Figs 1E-1G show similar 
localization and distribution of the CTPR390-488 protein when detected by fluorometry 
and through immune-detection with the CTPR390-specific antibody in TGFβ-activated 
fibroblasts treated with 0.4 μM of CTPR390-488. Figs 1H-1J show the WB detection 
and quantification of intra and extracellular CTPR390-488 protein in treated fibroblasts. 
The densitometric analysis of CTPR390-488 indicated that 7.72% was inside the cell 
after 24 hours (Fig 1J). These results showed that CTPR390-488 is efficiently 
internalized in primary cardiac fibroblasts without affecting the viability of the cells. 
2.2 CTPR390-488-Hsp90 interaction does not reduce 
Hsp90 chaperone activity 
We utilized fluorescence anisotropy to monitor the interaction between CTPR390-488 
protein and the Hsp90 C-terminal peptide and determine the corresponding binding 
affinity (Fig 2A). The results demonstrate that the capability of the protein to recognize 
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the Hsp90 C-terminal peptide was not affected by the cysteine modification. 
Furthermore, the KD value obtained for the interaction was 110 ± 7 μM, comparable to 
the value obtained previously [15]. Refolding assays were used to determine Hsp90 
ATPase activity in the presence of increasing concentrations of CTPR390-488 in 
myocardial fibroblasts (Fig 2B). We did not observe reduction on Hsp90 chaperone 
activity in any of the groups (WT control, Hsp90aa1 KO, WT+CTPR390-488, 
KO+CTPR390-488) at increasing concentrations of the inhibitor (0.1, 0.2, 0.4, 0.8 1.5 
and 3 μM). We found significant increases in refolding activity when adding 0.4; 0.8 or 
3 μM of CTPR390-488 compared to control fibroblasts (*p<0.05). Rabbit reticulocyte 
lysate was used as positive control (**p<0.005) and denatured luciferase in the 
absence of Hsp90 as negative control (***p<0.001) (Fig 2B). Gene expression of 
Hsp90aa1 slightly increased in WT fibroblasts with the CTPR390-488 treatment and 
Hsp90aa1 was not detected in Hsp90aa1 KO fibroblasts as expected (Fig 2C). Gene 
expression of Hsp90ab1 was reduced in KO cells compared to WT fibroblasts 
(***p<0.001) (Fig 2D). The significant variations of Hsp90 chaperone activity were not 
due to changes in Hsp90 protein levels (Fig 2E-2F). We did not find any Hsp90 
overexpression in Hsp90aa1 KO cells treated with CTPR390-488 either (Fig 2E-2F). 
Thus, the presence of CTPR390-488 did not alter the Hsp90 mRNA or protein 
expression, and the cellular effects observed in the presence of CTPR390-488 were 
not due to changes in Hsp90 expression. Activation of fibroblasts is ligand-dependent 
and TGFβ triggered Hsp90 mRNA and protein expression (Fig S1) and collagen 
synthesis [10] in myocardial fibroblasts. 
2.3 Co-localization of Hsp90 and CTPR390-488 
CTPR390-488 is an engineered TPR-based protein domain with Hsp90 binding 
properties [15, 24, 25]. We previously reported, that the extracellular domain of TGFβRI 
seems to interact with the Hsp90 dimer, and both Hsp90 isoforms (α and β) can be 
secreted extracellularly and be part of the Hsp90 dimer [10]. Here, we observed the co-
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localization of Hsp90 and TGFβRI in primary fibroblasts extracted from the myocardium 
of WT mice cultured in the presence of TGFβ (0.3 ng/ml) (Figs 3A-3D), and the co-
localization of Hsp90 and CTPR390-488 (Figs 3E-3I). We did not detect the triple co-
localization (Hsp90/ TGFβRI/ CTPR390-488). We included in the Discussion a possible 
mechanism of action that disrupts Hsp90-TGFβRI complex due to the presence of 
CTPR390-488. 
2.4 Collagen and p-Smad2/3 expressions were reduced 
in CTPR390-488-treated fibroblasts and fibroblasts from 
Hsp90aa1 KO mice 
To explore the collagen production and TGFβ signaling activity in the presence of 
CTPR390-488, primary cardiac fibroblasts from WT mice were treated with CTPR390-
488 (0, 0.1, 0.2 and 0.8 μM) and compared to primary cardiac fibroblasts from 
Hsp90aa1 KO mice (Fig 4). The results showed significant reduction in gene and 
protein expression for collagen I and collagen III upon treatment with increasing 
concentrations of CTPR390-488 (Figs 4A-4D). The quantification of collagens from 
Hsp90aa1 KO cells also exhibited lower gene and protein expressions compared to 
WT control (Figs 4A-4D). Collagen levels of Hsp90aa1 KO fibroblasts were also 
reduced upon treatment with CTPR390-488 compared to control KO cells (Fig S2A-
S2C). COL I deposition is lower in CTPR390-488-treated WT fibroblasts compared to 
control cells (Figs 4E-4H). Immunofluorescence studies showed a higher area of 
collagen deposition in WT cells (Fig 4F) than in CTPR390-488-treated cells (Fig 4H). 
Quantification of the immunofluorescence results concluded that the collagen area 
(COL I) in WT cells (67.4% ± 6.5) was higher than in CTPR390-488 treated cells 
(36.9% ± 13.7 (**p<0.005)) (Fig 4I). The reduction of in vivo COL I deposition from 
Hsp90aa1 KO myocardial fibroblasts was previously described by our group [10]. 
Furthermore, TGFβ-induced Smad2/3 phosphorylation was reduced by the addition of 
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CTPR390-488 (Fig 4J-4K). TGFβRI was found to be a Hsp90 interacting protein [27] 
and Hsp90 inhibition can affect TGFβRI protein levels. Thus, we also analyzed the 
expression of TGFβRI and other Hsp90 well known interactors not directly related to 
the canonical Smad TGFβ signaling cascade (Akt, Erk and Hsp70) by Western blot 
analysis. Cardiac fibroblasts were treated with different doses of CTPR390-488, 
including doses effective in reducing collagen production. We did not observe 
differences in protein expression (Fig S2D-S2J) of any of the tested Hsp90 interactors. 
This result would sustain the ability of CTPR390-488 to maintain Hsp90 chaperone 
activity thus avoiding cellular homeostasis disruption. It has been shown that higher 
concentrations of CTPR390 (40 μM) induces a substantial decrease in the 
phosphorylation of Hsp90 client protein Her2 (p-Her2) in cancer cells [16]. Similar to 
those observations, the levels of the p-Smad2/3 was also diminished (Fig 4K) as it 
were the phosphorylation levels of Akt and Erk (Fig S2D, S2E, S2G). Akt and Erk 
activation are TGFβRI dependent in fibrotic processes, so its activation could be 
diminished by a reduction in TGFβRI effectiveness upon Hsp90 inhibition as it was 
shown for pulmonary fibrosis [28]. To show that CTPR390-488 indeed promoted 
inactivation of the TGFβ receptor complex, we transfected a constitutive active TGFβRI 
(TGFβRI-CA, kindly sent by Dr. Bartholin, TGFβ and Pancreatic Cancer – Lab Centre 
de Recherche en Cancérologie de LYON (CRCL)) and observed that CTPR390-488 
was not able to influence pSmad2/3 or pErk expression (Fig S2K, S2L, S2M). 
2.5 CTPR390-488-treated fibroblasts and fibroblasts 
from Hsp90aa1 KO mice showed significant reduction 
of collagen extracellular deposition 
The differences among the ultrastructural features of myocardial primary fibroblasts 
from WT mice, CTPR390-488-treated WT mice and from Hsp90aa1 KO mice were 
analyzed using electron microscopy technique. Figs 5A and 5B shows engrossed 
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endoplasmic reticulum because of activated WT fibroblasts synthesizing proteins. WT 
fibroblasts also exhibited abundant deposition of extracellular collagen fibers (Fig 5B (1 
μm) Fig 5C (500 μm) pointed with arrows). CTPR390-488-treated fibroblasts showed 
much thinner endoplasmic reticulum and unstructured collagen fibers extracellularly 
deposited (Figs 5D-5F). We did not find CTPR390-488 associated to any cellular 
organelle (Fig S3). In the case of myocardial fibroblasts from Hsp90aa1 KO mice, more 
longitudinal shaped cells (Figs 5G-5H) with thinner endoplasmic reticulum (Fig 5I) and 
the absence of collagen deposition were observed. 
2.6 Cell motility is diminished in CTPR390-488-treated 
fibroblasts and fibroblasts from Hsp90aa1 KO mice  
Type I collagen is the major protein component of fibrous connective tissues, and 
fibroblasts are the cell type primarily responsible for collagen biosynthesis. Cells 
interacting with collagen network form an arrangement through local matrix. This 
patterning allows the establishment of tracks for fibroblasts migration and colonization 
[29-31]. WT myocardial primary fibroblasts were tracked to observe their migration 
during 20 hours after activation with TGFβ (0.3 ng/ml).  The average path length per 
WT cell was 273 ± 24 μm (Figs 6A, 6G). When cells were treated with 0.2 μM of 
CTPR390-488 the path length travelled decreased significantly (147 ± 19 μm, 
***p<0.001) (Figs 6C, 6G); similar to the Hsp90aa1 KO fibroblasts (143 ± 9 μm, 
***p<0.001) (Figs 6E, 6G). The collagen secreted to the extracellular media is the main 
component of the extracellular matrix and the extracellular matrix is the key biological 
system involved in the progression of disease [32]. The reduction in motility of the 
CTPR390-488-treated cells can be recovered to initial values culturing the cells on 
synthetic extracellular matrix (Matrigel) (241 ± 10 μm, ***p<0.001) (Figs 6D, 6G). The 
Hsp90aa1 KO cells on Matrigel also exhibited a certain recovery in their motility but 
they did not reach the path length values of WT cells (182 ± 24 μm, *p < 0.05) (Fig 6F, 
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6G). The motility of WT control cells was unaltered on the synthetic matrix (242 ± 20 
μm) (Fig 6B, 6G). Fig S4 shows the individual cell paths of each assay. 
2.7 In vivo administration of CTPR390-488 reduced 
myocardial fibrosis in Angiotensin II-treated mice  
We administrated Ang II to promote the activation of the TGFβ-dependent pro-fibrotic 
process in the heart of WT and Hsp90 KO mice (see Fig S5A to check in vivo 
experimental design). Myocardial Hsp90 chemical inhibition reduces TGFβ signaling 
cascade [10, 33-35]. Mice received a constant infusion of Ang II (0.25 μl per hour, 14 
days); and one dose (1mM) of CTPR390-488 was administrated intraperitoneally. The 
administration of CTPR390-488 did not alter mice behavior and no sign of discomfort 
was observed. We measured CTPR390-488 plasma concentrations at different time 
points for a duration of 2 weeks after its administration, (Fig S5B-S5C). After 7 days of 
CTPR390-488 administration collagen I and III reached the lowest levels of gene 
expression (Fig S5D-S5E). One week later, the presence of CTPR390-488 was not 
detected in plasma and the collagen expression increased (Fig S5D-S5E). Thus, 7 
days after CTPR390-488 injection and 14 days after Ang II minipump implantation was 
a good time-point to determine the effects on gene and protein expression.  
TGFβ gene expression in WT+Ang II mice compared to Sham littermates was 
increased (458.2 ± 39.4 vs 277.3 ± 31.2 **p<0.005). Furthermore, TGFβ gene 
expression in WT+Ang II mice treated with CTPR390-488 was also elevated, while 
Hsp90aa1 KO mice showed lower levels of TGFβ (**p<0.005) (Fig 7A). We also 
evaluated the activation of the canonical signaling mediator of TGFβ, Smad2/3, in heart 
samples from WT mice treated with Ang II, and we observed significant higher levels of 
protein phosphorylation compared to control mice (16470.7 ± 880.3 vs 5380.1 ± 1238.5 
a.u. ***p<0.001) and a significant reduction when those mice were treated with 
CTPR390-488 **p<0.005) (Fig 7B). In vivo, collagen I and III expression increased 
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upon Ang II treatment (p<0.05*) and they both were reduced in WT+Ang II+CTPR390-
488 mice (p<0.05*) compared to Ang II-treated mice (Figs 7C and 7D). The Hsp90aa1 
KO mice did not exhibited changes in TGFβ, COL I, COL III gene express ion nor 
Smad2/3 phosphorylation with Ang II, or Ang II+CTPR390-488 treatment compared to 
Hsp90aa1 KO sham mice. TGFβ (**p<0.005), COL I (**p<0.005), COL III (*p<0.05) 
gene expression and Smad2/3 phosphorylation (*p<0.05) were significantly reduced in 
Hsp90 KO compared to WT+Ang II mice, (Figs 7A-7D).  
2.8 Systemic CTPR390-488 levels increased in 
Angiotensin II-treated mice 
The endogenous fluorescence of CTPR390-488 allowed its detection in plasma. To 
obtain the calibration curve of the assay a serial dilution of CTPR390-488 (83.3; 41.7; 
20.8; 10.4; 5.2 and 0 μM) was added to plasma of WT mice, and the fluorescence 
signal obtained for each concentration was adjusted to a second order polynomial 
(quadratic) curve (Fig 7E). We checked the CTPR390-488 signal at different time-
points (1 hour, 5 days, 7 days and 14 days) after CTPR390-488 administration to the 
different groups of mice in the study (see Fig S5C); we also generated the calibration 
curve for each time point (Fig S5B). Mice subjected to Ang II osmotic infusion for 14 
days and CTPR390-488 treatment for 7 days were chosen for the in vivo 
measurements. The control groups without Ang II showed significant lower levels of 
CTPR390-488 compared to the Ang II counterparts (0.02 μM ±0.01 vs 0.80 μM ±0.10, 
**p<0.005; 0.007 μM ±0.004 vs 0.05 μM ±0.01, **p<0.005) (Fig 7F). In contrast, we 
observed that the CTPR390-488 plasma levels were higher in the WT+Ang 
II+CTPR390-488 group compared to KO+Ang II+CTPR390-488 (0.80 μM ±0.10 vs 0.02 
μM ±0.01, **p<0.005) (Fig 7F). 
2.9 CTPR390-488 myocardial accumulation  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
The histological assessment (Fig 8), showed that CTPR390-488 is accumulated at the 
left ventricle of WT+Ang II mice treated with CTPR390-488 (Fig 8D) to a higher extent 
than their correspondent WT+CTPR390-488 control group (Fig 8H) or KO+Ang 
II+CTPR390-488 mice (Fig 8L) (10.5%±1.5, 1.3%%±0.4, 0.3%±0.2, ***p<0.001 see 
measurements in Fig S6A-S6D). We checked that both myofibroblasts took up 
CTPR390-488 in vivo as well as cardiomyocytes (Fig S6E-S6F). WT+Ang II mice 
treated with CTPR390-488 presented reduced fibrosis compared to the non-treated 
mice (Figs 8B compared to 8C). Fig 8A showed the combinatory image of myocardial 
tissue section showing collagen fibers (blue) and the CTPR390-488 detection (green). 
In the WT+CTPR390-488 mice (Figs 8E-8H) or the Hsp90aa1 KO+Ang II mice (Fig 8I-
8L) the fibrotic areas were barely detectable in both groups presenting similar 
appearance. 
 
 
 
 
3 Discussion 
 
The data presented here suggest that the blockade of Hsp90 with an engineered 
Hsp90 protein inhibitor (CTPR390-488) in myocardial fibroblasts effectively attenuated 
the canonical TGFβ signaling cascade. The consequences of this modulation promoted 
lower levels of collagen production and collagen deposition in vitro and in vivo.  
We confirmed that the phosphorylation of Smad2/3 signaling effector and the 
phosphorylation of the non-Smad TGFβ downstream signaling molecules (Akt and Erk) 
[36] was decreased in the presence of CTPR390-488, while their protein expression is 
not affected. The preserved folding activity and the unaltered protein expression of 
Hsp90 client proteins (Akt, Erk, Hsp70 and luciferase) indicated that Hsp90 inhibition 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
13 
 
by CTPR390-488 was affecting downstream effectors of TGFβRI without altering 
Hsp90 client proteins. TPR binding domain of the Hsp90 co-chaperones is crucial for 
the Hsp90 protein-protein interactions and functional complexes formation. CTPR390-
488 is an engineered protein presenting an active Hsp90 TPR binding domain that can 
disrupt the TGFβRI–Hsp90 complex by mimicking the co-chaperone Hsp90-binding 
domain. Considering the interaction interface observed in the Hsp90-TGFβRI model 
the conformational change to the open state will disrupt the Hsp90 surface interaction 
in which the two monomers participate, thus destabilizing Hsp90-TGFβRI complex [7, 
10]. We hypothesized that CTPR390-488 binding promotes conformational change to 
open the close Hsp90 dimeric conformation and expulse TGFβRI (Fig 3J). The crystal 
structure of the CTPR390-488 domain in complex with the Hsp90 peptide confirmed 
the mechanism of recognition, mimicking the natural TPR domains that bind the C-
terminal sequence of Hsp90 [25]. The specificity of the interaction has been tested by 
biophysical characterization [15] and in cell culture [16]. The interaction of the 
extracellular domain of TGFβRI with Hsp90 homodimers occurs when Hsp90 is in a 
closed conformation [10]. The binding of TPR domain to the C-terminal end of Hsp90 
has been shown to promote a conformational change of Hsp90 from the closed state to 
the open state [26]. Therefore, it is expected that the binding of CTPR390-488 protein 
to Hsp90 shift its conformational equilibrium toward the open state. 
In our previous work [10], we demonstrated that both, Hsp90aa1 and Hsp90ab1 
isoforms can be secreted into the extracellular medium and could be part of the Hsp90 
dimer bound to TGFβRI. Moreover, CTPR390-488 does not distinguish between Hsp90 
isoforms as shown by the reduction in collagens I and III in Hsp90aa1 KO and WT 
cells. We assume that it also acts on the inducible isoform Hsp90aa1 whose deletion 
also promotes lowering of TGFβ pro-fibrotic related signaling through phopsho-
Smad2/3, as well as collagen I and collagen III production. In any of these cases, 
Hsp90 lost its chaperon activity. The specific binding of CTPR390-488 to the C-terminal 
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end of Hsp90 displayed binding affinity similar to the endogenous TPR domains and 
allowed the maintenance of the ATPase dependent Hsp90 chaperone activity.   
Cardiac fibroblasts together with cardiomyocytes are the most prevalent cell types in 
the myocardium [37, 38]. Under pathological conditions, cardiac fibroblasts proliferate 
and increase their motility. The remodeling process includes the colonization of new 
areas with increase of the total interstitial fibrosis, which in the long term enhances 
intrinsic myocardial stiffness and results in diastolic dysfunction [39]. The interstitial 
fibrosis is facilitated by the increased extracellular matrix deposition [36] reduced in 
Hsp90aa1 KO primary fibroblasts or in the cells treated with the CTPR390-488 protein. 
Both CTPR390-488 treated-primary fibroblasts and fibroblasts from Hsp90aa1 KO mice 
exhibited lowered cell motility compared to WT cells. The motility was recovered when 
cells were cultured on a collagen matrix surface. Thus, the CTPR390-488 protein, likely 
through its disruption of the Hsp90/TGFβRI complex, promotes a reduction of collagen 
accumulation in the extracellular matrix, which influences cell motility.  
Persistent fibroblast activation is considered responsible for excessive extracellular 
matrix production and involves tight regulation of the main pro-fibrotic TGFβ signaling 
cascade. The deletion of Hsp90 affects cell response in myocardial remodeling [9]. 
Ultrastructural studies of C PR390-488 treated-fibroblasts interestingly showed 
intercellular unstructured collagen fibers. We also observed thinner endoplasmic 
reticulum in the CTPR390-488 treated fibroblasts (as it is the case also for the 
Hsp90aa1 KO fibroblasts), while the WT fibroblasts presented engrossed endoplasmic 
reticulum as it would be expected in TGFβ-activated fibroblasts synthesizing collagens.  
The rapid advances in understanding the pathophysiology of fibrosis have generated 
intense interest in developing effective anti-fibrotic therapies for patients with chronic 
myocardial diseases. With no agents yet approved for this indication, considerable 
efforts are being invested in developing therapies and novel markers  for myocardial 
fibrosis. These studies using an engineered protein inhibitor, CTPR390-488, is proof of 
concept to focus our scientific efforts by exploiting the Hsp90 biology.  The ability of 
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fluorescently tracking the protein is of special interest in the field of the biomedical use 
but most importantly is the lack of toxicity when it is internalized by human ductal 
breast cancer cells [16] or myocardial fibroblasts as we showed herein. 
We investigated the in vivo reduction of myocardial fibrosis with the use of the 
CTPR390-488 protein in WT and Hsp90aa1 KO mice subject to angiotensin II (Ang II) 
infusion. The systemic administration of Ang II induces cardiac fibroblasts activation 
including the production and release of the pro-fibrotic cytokine TGFβ [40, 41]. TGFβ 
expression is induced by angiotensin II in kidney, vascular smooth muscle cells, and in 
cardiac fibroblasts [35]. We utilized the Ang II fibrotic mouse model since angiotensin II 
receptor blockade were mainly attributed to a reduction in extracellular protein 
accumulation, most likely mediated through inhibition of TGFβ and its downstream 
signals [42]. Blockade of the Ang II-TGFβ signaling pathway has consistently been 
demonstrated to be effective for the prevention of cardiac fibrosis in experimental 
animals [43-45]. In this study, we show reduction in the accumulation of collagen in the 
heart of the Ang II treated-mice upon the CTPR390-488 peptide administration or by 
Hsp90aa1 deletion. This observation suggests that a role of Hsp90 in this fibrotic 
process and that the inhibition of its TPR binding domain (linked to TGFβRI) is enough 
to diminish collagen deposition, collagen expression and TGFβ signaling cascade 
activation. 
Moreover, the higher presence of CTPR390-488 protein in the left ventricle and plasma 
of fibrotic mice compared to control mice indicated its accumulation in fibrotic areas. 
These observations open the possibility of studying the CTP390-488 protein as a new 
anti-fibrotic therapy that could also be utilized as a biomarker of the disease. The 
inhibition of Hsp90 with small molecules produces important side effects in the clinic 
due to the ATPase activity annulment [46]. We presented here a trackable and 
potentially safe biomolecule, CPTR390-488, as the first in vivo myocardial anti-fibrotic 
bio-therapy.  
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4 Conclusions  
Hsp90 inhibition is reached using an engineered protein CTPR390-488, this inhibition 
likely affects the Hsp90-TGFβRI interaction and it promoted the reduction of key 
myocardial pro-fibrotic events both in vitro and in vivo. We give an insight into the 
mechanism of action that would support the hypothesis of Hsp90 and TGFβRI 
partnership regarding the myocardial fibrotic process. Hsp90 inhibition implies TGFβ 
signaling deregulation and collagen synthesis reduction. Preservation of Hsp90 folding 
activity by inhibiting the chaperon with CTPR390-488 offers a new way of targeting left 
ventricle remodeling without damaging cell homeostasis.  
 
 
5 Materials and Methods 
 
5.1 Protein Expression and Purification 
CTPR390-Cys protein was produced by the introduction of a single C-terminal cysteine 
in CTPR390 [15] by quick change mutagenesis. CTPR390-cys was expressed as 
previously described [15, 47]. Briefly, CTPR390-Cys gene cloned in pProEx-HTA 
vector, coding for N-terminal (His)6 tag and ampicillin resistance, was transformed into 
Escherichia coli C41 (DE3). Overnight bacteria culture in 50 mL of Luria–Bertani (LB) 
media containing 100 μg mL−1 of ampicillin was grown to saturation. 10 mL of the 
saturated culture were diluted into 1 L of LB media supplemented with 100 μg mL−1 
ampicillin. The cells were grown in an incubator-shaker (250 rpm) at 37°C to an optical 
density (OD600) of 0.6–0.8. Expression of CTPR390 was induced with 0.6 mM isopropyl 
β-d-thiogalactoside (IPTG) followed by 5 h expression at 37°C. The cells were 
harvested by centrifugation at 5000 rpm for 20 min. The cell pellets were resuspended 
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in lysis buffer consisting of 300 mM sodium chloride, 50 mM Tris pH 8.0. After 2 min 
sonication at 30% power using a microtip and Mison sonicator, lysed cells were 
centrifuged at 16000 rpm for 30 min and the protein supernatant was purified using 
standard Ni-NTA affinity purification protocol. The N-terminal hexahistidine tag was 
then cleaved using TEV protease. As a final step, the CTPR390-Cys was dialyzed 
against 150 mM NaCl, 50 mM phosphate buffer pH 7.4. Protein concentration was 
measured by UV absorbance at 280 nm, using extinction coefficients at 280 nm 
calculated from amino acid composition.  
 
 
5.2 Ligand binding experiments 
 
CTPR390-Cys protein binding affinity to Hsp90 C-terminal peptide was determined by 
fluorescence anisotropy titrating with increasing amounts of protein into a 50 nM 
fluorescein-labeled Hsp90 peptide solution [47-49]. Fluorescence anisotropy was 
recorded exciting at 492 nm with a 5 nm slit width and recording the emission at 516 
nm with slit widths of 5 nm. G-factor corrections to account the difference in 
transmission efficiencies of the two emission channels were applied to calculate 
anisotropy using PBS buffer as blank solution and a 50 nM fluorescein as a standard 
solution. Anisotropy values are automatically calculated.  The fraction of peptide bound 
at each point in the binding curve was calculated by the equation [15]: 
 
%
f
b f
r r
Bound
r r



 
where r is the observed anisotropy of the peptide at any protein concentration, rf is the 
anisotropy of the free peptide and rb is the anisotropy of the peptide bound to the 
protein in the plateau region of the binding curve. The percentage of peptide bound is 
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plotted versus the protein concentration. The data were fit to a 1:1 binding model using 
Origin to calculate the dissociation constant. 
 
 
5.3 CTPR390 labeling with Alexa 488 to obtain 
CTPR390-488 
 
CTPR390-Cys protein was labeled with the cysteine-reactive maleimide form of Alexa 
Fluor 488 (Molecular Probes, Inc.) dye through the cysteine at the C-terminal following 
previously described protocols [24]. Briefly, CTPR390-Cys protein at 100 μM 
concentration was reduced by incubation with 10 mM 1,4-dithio-DL-treitol (DTT) for 15 
min. DTT was removed by gel filtration over a PD-10 column against 150 mM NaCl and 
50 mM phosphate (pH 7.0). A solution of Alexa Fluor 488 maleimide in water was 
added dropwise into the freshly reduced protein in the presence of 1 mM tris(2-
carboxyethyl)phosphine to a final 1:5 protein:dye molar ratio. The reactions were 
allowed to proceed for 4 h at room temperature under a non-reducing atmosphere of N2 
in the dark. The free dye was removed from the reaction mixtures by two consecutive 
buffer exchange steps over PD-10 columns, followed by concentration and extensive 
washing using Amicon ultrafiltration tubes with a MWCO of 10-kDa. The extent of 
labeling was calculated from the absorption spectra of the conjugate and using the 
extinction coefficient for Alexa Fluor 488 ε493 = 72,000 M−1 cm−1 and the protein 
extinction coefficient at 280 nm calculated from the amino acid composition. 
 
 
5.4 Cultured primary cardiac fibroblasts 
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Adult cardiac fibroblasts from mice C57BL6 strain (wild type) and the transgenic 
Hsp90aa1 KO were originally isolated directly from enzymatically digested hearts 
(collagenase, trypsin and DNase) followed by centrifugation and filtration. They were 
maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% FBS, 10% 
DBS and 100 U/ml penicillin-streptomycin. The cells (2 × 105) were plated in 35 mm 
tissue culture dishes and, 4 h later, recombinant TGFβ1 (0.3 ng/ml) (R&D Systems) 
was added with or without CTPR390-488 (0.2 μM) 24 hours later cells were lysed and 
stored at − 80°C. Results included triplicate of three independent assays. Vimentin 
marked for positive fibroblasts. For experimental procedures, low passage cells (p2) 
were seeded onto 35 mm cell culture dishes and incubated at 37°C in 5% CO2 for 15–
20 h.  
 
 
5.5 Fluorescence and immunofluorescence assays  
 
The immunofluorescence assays of Hsp90 were performed using TGFβ-treated (0.3 
ng/ml for 24 h) primary myocardial fibroblasts and adding 0.2-0.8 μM of CTPR390-488. 
Paraformaldehyde fixed cells were incubated with mouse primary antibody against 
Hsp90 (Abcam). We utilized anti-mouse secondary antibody conjugated with Cy3 to 
detect Hsp90, (Jackson ImmunoResearch, USA). CTPR390-488 was detected with 
FITC filters and PureBlu Hoechst 33342 (Bio-Rad) was used as nuclear staining dye. 
LSM-510 laser scanning microscope (Carl Zeiss Inc., Germany) was utilized for these 
experiments using an objective Plan Apo VC 60 × Oil DIC N2. 
 
 
5.6 Cell viability assay 
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Cell viability was assessed in TGFβ-treated cells (0.3 ng/ml for 24 h) in the presence or 
absence of CTPR390-488. Cells samples were diluted in DMEM medium, PBS 1X, pH 
7.4 and 0.4% trypan blue solution (Gibco®-Life technologies) and viability measured by 
the utilizing Countess®Automated Cell Counter and following the manufacturer's 
protocol (Countess®Automated, Invitrogen). 
 
 
5.7 Absorption and fluorescence spectroscopy 
The absorbance of the CTPR390-488 treated cells was measured at 488 nm with a 
NanoDrop instrument (Thermo Scientific) including a calibration curve (3.0, 1.5, 0.8, 
0.4, 0.2, 0.1 and 0 μM of CTPR390-488). 
 
Fluorescence measurements of CTPR390-488 signal were performed with 96 well 
black/clear plates in a Berthold Mithras LB 940 spectrofluorometer. The 
excitation/emission wavelengths were 485/535 nm. Fluorescence was measured from 
primary cell lysates and plasma samples containing CTPR390-488. 
 
 
 
5.8 Functional refolding assay 
 
To determine Hsp90 chaperone activity we measured the ability of Hsp90 to refold 
denatured luciferase, which will ultimately catalyze the luciferin reaction. The luciferase 
renaturation assay was performed in 96-well clear bottom plates containing 25 μg of 
protein lysate from TGFβ-treated (0.3 ng/ml for 24 h) cells isolated from the left 
ventricle mice. The refolding reaction was initiated by the addition of the denatured 
luciferase (1.5 μg/ml, denatured at 46°C for 10 min, in presence of TGFβ (0.3 ng/ml) to 
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the lysate containing Hsp90 or Hsp90+CTPR390-488. Once luciferase is renatured 
after 2h incubation at room temperature, it will catalyze the luminescent reaction with 
luciferin. The luciferase activity was measured by addition of Luciferase Assay Reagent 
(E1501, Promega). The source of Hsp90 was WT primary myocardial fibroblasts and 
primary myocardial fibroblasts of Hsp90aa1 KO mice. The negative control utilized 
corresponded to the substrate (heat-denatured luciferase) in the absence of Hsp90 and 
the positive control corresponded to rabbit reticulocyte lysate (RRL) with high content 
of Hsp90. Light emission from each micro well was recorded with a 1 s integration time 
using a Berthold Centro LB 960 plate reader 3 min after addition of the luminescent 
reagent. Results included triplicate of three independent assays. Buffers and reagents 
were previously described more in detail by Eachkoti et al. [50].  
 
 
 
5.9 Determination of mRNA expressions by Q-PCR 
 
Total mRNA from cells and tissue samples were assayed by Q-PCR; Cell samples 
were cultured with recombinant TGFβ1 (0.3 ng/ml) with CTPR390-488 and TGFβ for 
24 h were obtained by TRIzol extraction (Invitrogen). The mRNA was reverse 
transcribed using random primers. The quantitative PCR (Q-PCR) were performed with 
specific TaqMan primers: Hsp90aa1, Hsp90ab1, COL I, COL III, TGFβ1, Smad2 and 
αSMA. The housekeeping gene was 18S in all cases. The values represented the 
average of three independent experiments. 
 
 
5.10 Protein detection by Western Blot 
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Protein expression was detected by Western blot analysis and densitogram 
quantification. Tissue samples were disrupted and lysated. Cell samples were treated 
with recombinant TGFβ1 (0.3 ng/ml) (Abcam) for 24 hours collected, the lysate was 
resolved on 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel and 
transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad Lab., California, 
USA). The primary antibodies used were: polyclonal anti Smad2/3 and p-Smad2/3 
(Santa Cruz); polyclonal anti GAPDH (Santa Cruz); and polyclonal anti COL I and COL 
III (Santa Cruz), monoclonal Hsp90 (Abcam). Secondary antibodies conjugated with 
IRDye 800CW and  IRDye 680RD were used for immunodetection. CTPR390-488 
protein detection was performed using anti-CTPR390 rabbit antibody purified from the 
serum from a rabbit immunized with CTPR390 (Unidad de Ensayos Biotecnológicos y 
Biomédicos, Servicios Científico Técnicos, Universidad de Oviedo). 
 
 
5.11 Transmission electronic microscopy 
 
Wild type, CTPR390-488 treated, and Hsp90aa1 KO primary cardiac fibroblasts were 
examined for conventional ultrastructural analysis. Cells were rinsed in 0.1 M 
phosphate buffer, fixed in 2 % osmium tetroxide, dehydrated in acetone, and 
embedded in araldite (Durcupan, Fluka, Switzerland). For immunogold electron 
microscopy, myocardial primary fibroblasts were fixed with 4% paraformaldehyde in 0.1 
M cacodylate buffer for 30 minutes at room temperature. Cells were scraped from the 
dishes, transferred to an Eppendorf tube, and centrifuged for 1 minute in a microfuge to 
obtain cell pellets. The pellets were washed with 0.1 M cacodylate buffer, dehydrated in 
increasing concentrations of methanol at -20°C, embedded in Lowicryl K4M at -20°C, 
and polymerized with ultraviolet irradiation. Ultrathin sections were mounted on nickel 
grids and sequentially incubated with 0.1 M glycine in PBS for 15 minutes, 5% BSA in 
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PBS for 1 hour, and the rabbit polyclonal anti-CTPR390-488 antibody diluted 1:50 in 
PBS containing 1% BSA and 0.1 M glycine for 1 hour. After washing, the sections were 
incubated with goat anti-rabbit IgG coupled to 15 nm gold particles (diluted 1:50 in PBS 
containing 1% BSA; BioCell, UK). After immunogold labeling. All grids were stained 
with lead citrate and uranyl acetate and examined with an 80KV electron microscope 
with Camara Orius SC 100 CCD and Software Gatan. For control, ultrathin sections 
were treated as described above, but without the primary antibody. 
 
5.12 Cell tracking 
 
Cell track assays were conducted with or without matrigel (3mg/ml) and activated with 
TGFβ (0.3 ng/ml). Images were captured overnight every 10 minutes following cell 
nuclei (marked with NucBlue Live ReadyProbes Reagent). The distance traveled by 
cells was obtained by quantification of segmented nuclei. The measurements of the 
distance travelled by the fibroblasts for 20 hours were done on cells plated on tissue 
culture plates with or without matrigel (3mg/ml) (Sigma-Aldrich) and activated with 
TGFβ1 (0.3 ng/ml). The data were obtained from 15-32 different areas per assay in 
triplicate and in three independent experiments. Cell track was captured with an 
epifluorescence microscope Nikon Ti, objective 10x plan fluor 0.30 NA. Phase contrast 
/ DAPI (387/25 exc-440/25 emis)/ FITC (485/20 exc-521/25 emis). The camera 
installed was Hamamatsu ORCA R2 and the Software Nis elements with the cell-
tracking module was utilized. 0.2 ug/ml of CTPR390-488 was utilized in three 
independent experiments. 
 
 
 
5.13 Simulations of protein-protein interactions  
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In silico prediction of the interaction between the Hsp90 dimer in close conformation 
(PDB ID: 2CG9) and the extracellular domain of TGFβRI PDB: 3KFD was described 
previously [10]. The CTPR390 structure was previously solved in complex with the C-
terminal peptide of Hsp90  (PDB ID: 3KD7) [25]. In order to model the ternary 
complexes including Hsp90-TGFβRI-CTPR390 proteins the flexible C-terminal region 
of Hsp90 proteins that is recognized by the TPR domain and does not appear in the 
crystal structured was modeled using UCSF Chimera interface with MODELLER [49].  
 
 
5.14 Animal studies 
 
Adult (16–20 weeks old) C57BL6 wild type (WT) mice or Hsp90aa1 KO mice were 
housed in a 22°C room with 12:12 h light/dark cycle and provided with food and water 
ad libitum. Mice were divided into 7 groups of n= 4 mice per group: WT, 
WT+CTPR390-488, WT+Ang II, WT+Ang II+CTPR390-488, Hsp90aa1 KO, Hsp90aa1 
KO+Ang II and Hsp90aa1 KO+Ang II+CTPR390-488. Live animals’ studies were 
approved by the University of Cantabria Institutional Laboratory Animal Care and Use 
Committee in compliance with the Guide for the Care and Use of Laboratory Animals 
(ILAR, 1985) and were conducted in accordance with the “European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes” 
(European Communities Council Directive 86/606/EEC). 
 
 
 
5.15 Mice handling 
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In vivo experimental design is shown in Fig S5A. The experimental time points 
indicated Ang II time of implantation, CTPR390-488 time of injection and samples 
collection time-points. Mice were placed on preheated pad set to prevent hypothermia 
and were anesthetized by inhaled isoflurane in oxygen/nitrous oxide mixtures at 2.0%. 
Under this anesthesia conditions we performed the following actions:  
 
 
5.15.1 Subcutaneous implantation of osmotic minipumps 
 A mid-scapular incision is made, and a subcutaneous pocket is created for the micro-
osmotic pump (0.25 μl per hour, 14 days, alzet) to be inserted. The pump was 
previously filled with an aqueous solution of angiotensin II (0.70 mg). The wound was 
closed with a suture. Mice were monitored daily for any discomfort and they were 
euthanized 2 weeks after surgery. 
 
 
5.15.2 CTPR390-488 intraperitoneal administration 
CTPR390-488 (200 μl of 1 mM) intraperitoneal (IP) administration. For the CTPR390-
488 intraperitoneal administration mice were anesthetized by 1.0-2.0% inhaled 
isoflurane in oxygen/nitrous oxide mixtures for 1 minute and injected 200 μl of 1 mM of 
CTPR390-488. Mice did not present any sign of discomfort.  
 
 
5.15.3 Plasma extraction 
Retro-orbital blood collection in mice was performed with animals fully anesthetized. 
Within 5 min of blood collection plasma was separated by centrifugation at 1000X g 
and store at -20ºC for posterior use. 
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5.16 Histological assessment of myocardial fibrosis 
and CTPR390-488 detection 
 
The hearts from the mice under study described in the section “animal studies” were 
isolated and fresh frozen after incubation in sucrose 30% for 24 hours. The degree of 
fibrosis was detected in 6 μm sections stained with Masson's trichrome assay. After 
trichromic staining, bright field images were acquired on an upright fluorescence 
microscope (Eclipse 80i, Nikon) using a 20x 0.5 NA or 40x 0.57 NA objective, a DS-Ri1 
color camera (1280x1024 pixels; 0.46μm & 0.23μm pixel size). Next, wide field-
fluorescence images of the same fields were acquired using excitation (472/30nm) and 
emission (520/35) filters. Finally, to reconstitute a RGB color image we added the 
green channel from the corresponding fluorescence image to the green channel of the 
trichrome staining image. The merged images of fluorescence and trichromic staining 
were obtained with ImageJ after splitting the trichromic RBG color images in 8bits 
individual channels (R: red, G: green, B: blue). 
 
 
5.17 Statistics and graphics program 
 
The data sets were assessed for normality using the Kolmogorov–Smirnov test. 
Continuous variables were compared using two-tailed Student's t-test or Mann–
Whitney U test. GraphPad Prism 5.03 was utilized as the statistical package and 
graphics program. 
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10 Figure Legends 
 
Fig 1: CTPR390-488 detection in primary fibroblasts from WT mice myocardial 
tissue. A: Confocal microscopy showing the intrinsic fluorescence (green) of 
CTPR390-488 both intra and extracellularly at two different concentrations (0.2 and 0.8 
μM) in living cells (not fixed). Right panels show the shape of the fibroblast in red. B: 
Cell viability at increasing concentrations of CTPR390-488. C, D: Absorbance and 
fluorescence values of a titration curve (pure CTPR390-488) and the correspondent 
CTPR390-488 signal at each concentration of intracellular samples. In all cases three 
independent experiments were performed. E, F, G: Co-localization of the two possible 
detection for CTPR390-488: its intrinsic Alexa 488 fluorescence and the CTPR390 
immuno-detection. E: merge images of F and G. F: Confocal microscopy of the 
CTPR390-488 intrinsic fluorescence. G: the immunofluorescence detection of 
CTPR390-488 using anti-CTPR390 antibody and Cy5 secondary antibody. H: WB of 
the CTPR390-488 pure molecule (C), and CTPR390-488 from the fibroblasts lysate 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
31 
 
and the supernatant (S). I, J: quantification of CTPR390-488 WBs from (H).  Significant 
variations of three independent experiments assayed were expressed vs. control (C), 
*p < 0.05, **p < 0.005, ***p < 0.001; Mann–Whitney test. 
 
Fig 2: Hsp90 binding and effect on Hsp90 chaperone activity of CTPR390-488. A: 
Fluorescein anisotropy assay showing Hsp90 binding activity of CTPR390-488 (KD = 
110 ± 7 μM). B: Hsp90-dependent refolding activity of lysates from WT and KO, 
myocardial fibroblasts adding CTPR390-488 different concentrations; the negative 
control (-) was denatured luciferase and the positive control (+) corresponded to rabbit 
reticulocyte lysate (RRL). C, D: Hsp90aa1 and Hsp90ab1 gene expressions in WT and 
Hsp90aa1 KO fibroblasts under increasing concentrations of CTPR390-488. E: 
Representative Western blot (WB) of Hsp90 expression in primary myocardial 
fibroblast of WT mice (C), Hsp90aa1 KO mice (KO) and WT and KO fibroblasts in the 
presence of different concentrations of CTPR390-488 (0.2; 0.8; 1.5 μM), GAPDH was 
used as control. F: Densitogram quantifying three independent experiments; data were 
expressed as mean ± SD of optical density in arbitrary units (A.U.). Significant 
variations of three independent experiments assayed were expressed vs. control (C), 
*p < 0.05, **p < 0.005, ***p < 0.001; Mann–Whitney. 
 
Fig 3: Confocal microscopy assays showing protein co-localization in 
myocardial fibroblasts and in silico prediction of CTPR390-488 mechanism of 
action. A: merge-image showing co-localization of Hsp90 and TGFβRI. B: Hoechst 
was used as nuclear staining. C, D: Hsp90 is visualized with Cy3 and TGFβRI with Cy5 
secondary antibodies. E: Co-localization of CTPR390-488 (green) and Hsp90 (red) in 
myocardial fibroblasts was detected in yellow and it was marked by white arrows. F: 
Hoechst was used as nuclear staining. G: intrinsic fluorescence of CTPR390-488 
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(green). H: vimentin marks the cellular shape (vimetin-Cy3 was placed in channel gray 
to merge the final image 3E with Image J software). I: Hsp90 is visualized with Cy5 
secondary antibody and included in channel red of the Image J software to merge the 
final image 3E.  Bar indicates 10μm. J: From left to right: Molecular model of the 
interaction between the TGFβRI extracellular domain and Hsp90 closed dimer; 
Interaction of CTPR390-488 protein with the C-terminal end of Hsp90 domain; Hsp90 
conformational change from the close to the open state upon CTPR390-488 
interaction; disruption of the interaction between Hsp90 dimer (cyan and dark blue) and 
TGFβRI (orange).   
 
 
Fig 4: Gene and protein expression of collagens and Smad2/3 from primary 
myocardial fibroblast of WT mice (WT), Hsp90aa1 KO mice (KO) and WT with 
CTPR390-488. A, C, J: Gene expression of collagen I (COL I), collagen III (COL III) 
and Smad2 presented as relative expression versus 18S ribosomal RNA. B, D, K: 
Representative Western blots (WB) of COL I, COL III, Smad2/3 and p-Smad2/3 and 
densitograms of three independent experiments. GAPDH was used as loading control. 
E, G: Confocal microscopy showing the immunofluorescence detection of collagen I in 
TGFβ-treated (0.3 ng/ml) primary fibroblasts from WT mice (E), and WT+CTPR390-
488-treated fibroblasts (G). Hoechst (blue) was used as a nuclear staining. Anti-rabbit 
secondary antibody conjugated with Cy5 detected COL I. F, H: Black and white images 
corresponding to E and G panels respectively. The calculated percentage of collagen I 
area was the sum of the values in square pixels of the collagen-detected 
correspondent to graphs F and H (I). The calculated area percentage of the selected 
pixels was given in calibrated units using ImageJ 1.52e software (Fig 4I). Data were 
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expressed as mean ± SD of optical density in arbitrary units (A.U.). (*p < 0.05, **p < 
0.005, ***p < 0.001; Mann– Whitney test).  
 
Fig 5: Representative electron microscopy images of primary myocardial 
fibroblasts activated with TGFβ (0.3 ng/ml) from control WT mice, WT+CTPR390-
488 treated mice and Hsp90aa1 KO mice. A, B: WT cells with engrossed 
endoplasmic reticulum (ER) (a detail is marked with arrow 2 in panel B). B, C: WT cells 
with intercellular collagen deposition (arrows 1 panel B and arrow 3 panel C). D, E, F: 
CTPR390-488 treated WT cells showing normal ER and no structured collagens fibers 
(arrow 4 panel E, and arrow 5 panel F) and no signs collagen accumulation. G, H, I: 
cells from Hsp90aa1 KO mice showing thinner morphology, no active ER (arrow 6 
panel I) and absence of collagen deposition. 
 
Fig 6: Path length and cell tracking analysis of myocardial primary fibroblasts 
followed for 20 hours. A, C, E: Representative cell tracks in different colors showing 
the motility of WT controls (A), WT+CTPR390-488 treated (0.2 μM) cells (C) and 
Hsp90aa1 KO cells respectively (E). Nuclei marked in red. B, D, F: Path length 
measurements of cells soaked in matrigel (m) (3mg/ml) under the same conditions of 
A, C and E respectively. Nuclei marked in red. G: The path length data obtained from 
15-32 different areas per assay in triplicate and in three independent experiments. (See 
S5 Fig for the analysis of the path length travelled (μm) versus time (h:min)). (*p < 0.05, 
***p < 0.001; Mann– Whitney test). 
 
 
Fig 7: Gene and protein expressions related to the pro-fibrotic process in the 
myocardium of WT and KO mice, treated with or without Ang II and CTPR390-
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488. The samples from left ventricle were extracted from the mice under study: WT, 
WT+CTPR390-488, WT+Ang II, WT+AngII+CTPR390-488, KO, KO+CTPR390-488, 
KO+Ang II, KO+AngII+CTPR390-488. (n=4 per group). A, B, C, D: These panels 
showed TGFβ gene expression (A), Smad2/3, p-Smad2/3 protein expression and p-
Smad2/3 quantification (in arbitrary units A.U.) (B), COL I gene expression (C), and 
COL III gene expression (D). E: Graph showing the fluorescent signal of CTPR390-488 
titration in plasma. F: Graph showing the plasma concentration of CTPR390-488 in the 
groups of mice under study, n= 4 per group. (*p < 0.05, ***p < 0.001; Mann– Whitney 
test). 
 
Fig 8: Representative histological fibrosis of left ventricles transversal sections 
of Ang II+CTPR390-488 WT mice, CTPR390-488 treated WT mice, and Ang 
II+CTPR390-488 Hsp90aa1 KO mice.  A, E, I: merge of Masson's trichrome staining 
and confocal images showing accumulation of collagen in blue and detection of 
CTPR390-488 in green. B, C, F, G, J, K: Collagen staining in blue by Masson's 
trichrome. D, H, L: Confocal microscopy showing CTPR390-488 in green. C, G and K 
are the correspondent controls of B, F, and J in the absence of CTPR390-488.  
 
 
11 Supplementary Figure Legends 
 
Fig S1: Activation of the Hsp90 expression upon TGFβ addition in myocardial 
fibroblasts. In all panels, “C” abbreviation indicates fibroblasts from WT cells and “KO” 
indicates fibroblasts from Hsp90aa1 KO cells. “C +TGFβ” abbreviation indicates the 
presence of TGFβ (0.3 ng/ml) in WT cells and “C no TGFβ” the absence of it. The 
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presence of 0.4 µM of CTPR390-488 was indicated with the abbreviation “0.4”. The 
same nomenclature was used for the KO cells. A, B: Hsp90aa1 and Hsp90ab1 gene 
expressions in WT (C) and Hsp90aa1 KO fibroblasts (KO) and CTPR390-488 (0.4 μM). 
C: Representative WB of Hsp90 protein expression in primary myocardial fibroblast of 
WT mice (C), Hsp90aa1 KO mice (KO) and WT and KO fibroblasts in the presence of 
TGFβ (0.3 ng/ml) and/or CTPR390-488 (0.4 μM), GAPDH was used as loading control. 
D: Densitograms of Hsp90 quantifying three independent WB experiments; data were 
expressed as mean ± SD of optical density in arbitrary units (A.U.). Significant 
variations of three independent experiments assayed were expressed vs. control (C) or 
control (KO), *p < 0.05, **p < 0.005; Mann–Whitney test. 
 
Fig S2: Representative Western blots (WB) and their densitograms of proteins 
directly related and not related to TGFβ canonical signaling cascade and TGFβ 
non-canonical signaling cascade extracted from primary myocardial fibroblasts.  
A: Representative WB of COL I and COL III from Hsp90aa1 KO myocardial primary 
fibroblasts. B, C: COL I and III densitograms of three independent experiments 
showing the protein expressions at increasing concentrations of CTPR390-488 in 
Hsp90aa1 KO fibroblasts. D: Representative WB showing the expression of Hsp90 
interactor proteins. E, F, G, H, I, J:  densitograms of p-Akt, Akt, p-Erk, Erk, Hsp70 and 
TGFβRI respectively in the absence and presence of CTPR390-488 (0.1, 0.2, 0.8 μM). 
K, L, M: pSmad and pErk WB and their densitograms of TGFβRI constitutively active 
TGFβRI-CA (CA) transfected fibroblasts with and without CTPR390-488. GAPDH was 
used as loading control in all WB. 
 
Fig S3: Immunogold electronic microscopy of CTPR390-488 in myocardial 
fibroblasts. Representative electron microscopy image showing the presence of 
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CTPR390-488 in primary cardiac fibroblasts treated with TGFβ for 24 hours. Scale Bar: 
1 μm CTPR390-488. CTPR390-488 cellular localization represented by black defined 
spots, some of them marked by arrows. C marked the cytoplasm and N the nucleus of 
the cell. 
 
Fig S4: Graphs showing the individual path length data of 20 hours cell tracking 
analysis of the cell population correspondent to Fig 6. The path length is shown in 
the “y” axis (μm) versus time (h:min) in the “x” axis;  the colored lines represented the 
motility of each individual cell tracked in Fig 6. A, C, E: Representative cell tracks 
showing the motility of WT controls (A), WT+CTPR390-488 treated (0.2 μM) cells (C) 
and Hsp90aa1 KO cells respectively (E). B, D, F: Analysis of cells soaked in matrigel 
(m) (3mg/ml) and then measured the path length under the same conditions of A, C 
and E.  
 
Fig S5: Experimental timeline and groups under study. A: Graph showing the 
experimental timeline where the vertical red bar shows Ang II minipump subcutaneous 
implantation and the start of the assay. The vertical green bar shows the intraperitoneal 
administration of CTPR390-488, 7 days after Ang II minipump implantation the grey bar 
marks the end of the assay. The graph also shows the tissue and blood sample 
collection time-points (red, green, grey and empty bars). B: The fluorescence signals of 
known concentrations of CTPR390-488 adjusted to a second order polynomial 
(quadratic) curve. CTPR390-488 was incubated in plasma at 37ºC during the 1 hour, 5, 
7 and 14 days to check the maintenance of the signal on time. In this graph, all the 
sample time points of CTPR390-488 from panel A are represented. C:  Concentration 
of CTPR390-488 from the plasma of mice. The rectangle points the chosen 
experimental point (7 days after CTPR390-488 administration) used in figure 7.  We 
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divided mice into 4 groups (WT, WT+CTPR390-488, WT+Ang II and WT+Ang II+ 
CTPR390-488) with n= 4 animals per group. D, E: COL I and COL III gene expressions 
in all experimental groups tested. Ang II+CTPR390-488 +7 days is marked to show the 
chosen experimental time point in figure 7.  (*p < 0.05, ***p < 0.001; Mann– Whitney 
test).  
 
 
Fig S6:  Presence of CTPR390-488 in the myocardium of the mice under study. 
The calculated area percentage of the selected pixels was given in calibrated units 
using ImageJ 1.52e software inverting the original image from Fig 8D-8L: Inverted 
black and white image of the CTPR390-488 intrinsic fluorescence from the sample 
WT+AngII+CTPR390-488 (Fig 8D). B: Inverted black and white image of the 
CTPR390-488 intrinsic fluorescence from the sample WT +CTPR390-488 (Fig 8H). C: 
Inverted black and white image of the CTPR390-488 intrinsic fluorescence from the 
sample KO+AngII+CTPR390-488 (Fig 8L). D: Percentage of CTPR390-488 area of 
WT+AngII+CTPR390-488 treated mice and WT+CTPR390-488 treated mice and 
KO+AngII+CTPR390-488 treated mice. (***p < 0.001; Mann– Whitney test). E, F: 
confocal image showing CTPR390-488 intrinsic green fluorescence detected in the 
heart of Ang II + CTPR390-488 (0.2 μM) treated mice. Cardiomyocytes were marked 
with phalloidin staining (E) and myofibroblasts with vimentin staining (F). 
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Highlights: 
-We propose the interaction between CTPR390-488 inhibitor and Hsp90 
chaperone preserving Hsp90 ATPase activity 
-Collagen expression, collagen deposition and fibroblast motility are reduced in 
myocardial fibroblasts upon CTPR390-488 addition or Hsp90aa1 deletion. 
- Angiotensin II infused mice presents increased myocardial fibrosis that is 
reduced in CTPR390-488 treated mice or Hsp90aa1 KO mice. 
-CTPR390-488 plasma concentrations increases in angiotensin II infused WT 
mice. 
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